While COVID-19 vaccination continues to provide the best protection, COVID-19 therapies are widely available to help treat eligible people who do get sick and are at risk of developing severe disease. Antiviral treatments for residents at risk for COVID-19 reduces their risk of hospitalization and death.
The antiviral Paxlovid, along with Veklury (remdesivir), are the preferred treatments for eligible residents with positive COVID-19 test results and who are at risk for progression to severe COVID-19. COVID-19 therapeutics should be considered for any COVID-19 resident who meets the eligibility criteria.
This
fact sheet provides valuable information for patients, families, and caregivers. Included in the fact sheet is a detailed summary of what Paxlovid is, how it can be used safely, and other considerations to help eligible residents and their families make an informed decision about the utilization of Paxlovid.